Midgard Science

Labs / ADME, DMPK & toxicology

Maxion® Therapeutics

Cambridge, United Kingdom · maxiontherapeutics.com

On your own

Free. Their own form.

Contact Maxion® Therapeutics directly

Through Midgard

Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.

Request a quote through Midgard

Maxion® Therapeutics develops protein therapeutics based on its KnotBody® technology for ion channel- and GPCR-driven diseases. It is based in Cambridge, United Kingdom, and is led by a management team including CEO Arndt Schottelius, co-founder and CTO John McCafferty, and co-founder and CSO Aneesh Karatt-Vellatt.

Their website has a general contact form; we send your quote request through it.

What they offer

  • KnotBody® protein therapeutic discovery

    Develops first-in-class and best-in-class protein therapeutics using KnotBody® technology for previously untreatable ion channel and GPCR-driven diseases.

What they work on

Modalities
Small molecule, Antibody
Therapeutic areas
chronic pain, autoimmunity, cardiovascular disease, ion channel diseases, GPCR-driven diseases
Sites
Cambridge, United Kingdom

Public records

Ownership
MAXION THERAPEUTICS LIMITED · GB GLEIF

Similar labs. Sparx BIO, Aclairo Pharmaceutical Development Group, Inc., ACM Global Laboratories, Allumiqs

Found in a contract services directory. Listing built from maxiontherapeutics.com. Work here? Claim this listing.

Maxion® Therapeutics · Midgard Science